To validate our concept of serum FGF21 level as a predictive biomarker in thyroid cancer, further long-term follow-up studies that measure the serum levels of FGF21 in patients with thyroid cancer at the initial diagnosis, after thyroidectomy, and in those with stable and recurred disease status are necessary. This evidence concerns the gene FGF21 and thyroid gland carcinoma.